| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
USC/Norris Comprehensive Cancer Center, Department of Urology, Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, California [G. L., F. A. G., P. A. J.], and Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, DK-8200 Aarhus N, Denmark [T. F. O., T. T.]
Hypermethylation of the promoters of cancer-related genes is often associated with their inactivation during tumorigenesis. Several preclinical and clinical trials have been developed to use DNA methylation inhibitors, such as 5-aza-2'-deoxycytidine (5-Aza-CdR) in attempts to reactivate silenced genes in human cancers. We used high-density oligonucleotide gene expression microarrays to examine the effects of 5-Aza-CdR treatment on human fibroblast cells (LD419) and a human bladder tumor cell line (T24). Data obtained 8 days after recovery from 5-Aza-CdR treatment showed that more genes were induced in tumorigenic cells (61 genes induced; 
4-fold) than nontumorigenic cells (34 genes induced; 4-fold). Approximately 60% of induced genes did not have CpG islands within their 5' regions, suggesting that some genes activated by 5-Aza-CdR may not result from the direct inhibition of promoter methylation. Interestingly, a high percentage of genes activated in both cell types belonged to the IFN signaling pathway, confirming data from other tumor cell types.
This article has been cited by other articles:
|
|
 |
|
  B.-G. Jeon, G. Coppola, S. D Perrault, G.-J. Rho, D. H Betts, and W A. King S-adenosylhomocysteine treatment of adult female fibroblasts alters X-chromosome inactivation and improves in vitro embryo development after somatic cell nuclear transfer Reproduction, June 1, 2008; 135(6): 815 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Heller, W. M. Schmidt, B. Ziegler, S. Holzer, L. Mullauer, M. Bilban, C. C. Zielinski, J. Drach, and S. Zochbauer-Muller Genome-Wide Transcriptional Response to 5-Aza-2'-Deoxycytidine and Trichostatin A in Multiple Myeloma Cells Cancer Res., January 1, 2008; 68(1): 44 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sandilands, V. G. Brunton, and M. C. Frame The membrane targeting and spatial activation of Src, Yes and Fyn is influenced by palmitoylation and distinct RhoB/RhoD endosome requirements J. Cell Sci., August 1, 2007; 120(15): 2555 - 2564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Wischnewski, O. Friese, K. Pantel, and H. Schwarzenbach Methyl-CpG Binding Domain Proteins and Their Involvement in the Regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 Gene Promoters Mol. Cancer Res., July 1, 2007; 5(7): 749 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ripperger, N. von Neuhoff, K. Kamphues, M. Emura, U. Lehmann, M. Tauscher, M. Schraders, P. Groenen, B. Skawran, C. Rudolph, et al. Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle cell lymphomas Haematologica, April 1, 2007; 92(4): 460 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Egger, A. M. Aparicio, S. G. Escobar, and P. A. Jones Inhibition of Histone Deacetylation Does Not Block Resilencing of p16 after 5-Aza-2'-Deoxycytidine Treatment Cancer Res., January 1, 2007; 67(1): 346 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Fridman, L. Tang, O. I. Kulaeva, B. Ye, Q. Li, F. Nahhas, P. C. Roberts, S. J. Land, J. Abrams, and M. A. Tainsky Expression profiling identifies three pathways altered in cellular immortalization: interferon, cell cycle, and cytoskeleton. J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2006; 61(9): 879 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ibanez de Caceres, E. Dulaimi, A. M. Hoffman, T. Al-Saleem, R. G. Uzzo, and P. Cairns Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res., May 15, 2006; 66(10): 5021 - 5028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Wischnewski, K. Pantel, and H. Schwarzenbach Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells Mol. Cancer Res., May 1, 2006; 4(5): 339 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Utriainen, J. Liu, T. Kuulasmaa, and R. Voutilainen Inhibition of DNA methylation increases follistatin expression and secretion in the human adrenocortical cell line NCI-H295R J. Endocrinol., February 1, 2006; 188(2): 305 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kim, J. Lapointe, G. Kaygusuz, D. E. Ong, C. Li, M. van de Rijn, J. D. Brooks, and J. R. Pollack The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer Cancer Res., September 15, 2005; 65(18): 8118 - 8124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Cote, P. W. Laird, and R. H. Datar Promoter Hypermethylation: A New Therapeutic Target Emerges in Urothelial Cancer J. Clin. Oncol., May 1, 2005; 23(13): 2879 - 2881. [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Laird Cancer epigenetics Hum. Mol. Genet., April 15, 2005; 14(suppl_1): R65 - R76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Liu, X-D Li, A Vaheri, and R Voutilainen DNA methylation affects cell proliferation, cortisol secretion and steroidogenic gene expression in human adrenocortical NCI-H295R cells J. Mol. Endocrinol., December 1, 2004; 33(3): 651 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pompeia, D. R. Hodge, C. Plass, Y.-Z. Wu, V. E. Marquez, J. A. Kelley, and W. L. Farrar Microarray Analysis of Epigenetic Silencing of Gene Expression in the KAS-6/1 Multiple Myeloma Cell Line Cancer Res., May 15, 2004; 64(10): 3465 - 3473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Liang, J. C. Y. Lin, V. Wei, C. Yoo, J. C. Cheng, C. T. Nguyen, D. J. Weisenberger, G. Egger, D. Takai, F. A. Gonzales, et al. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome PNAS, May 11, 2004; 101(19): 7357 - 7362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T.C. Chan, Q. Tao, K. D. Robertson, I. W. Flinn, R. B. Mann, B. Klencke, W. H. Kwan, T. W.-T. Leung, P. J. Johnson, and R. F. Ambinder Azacitidine Induces Demethylation of the Epstein-Barr Virus Genome in Tumors J. Clin. Oncol., April 15, 2004; 22(8): 1373 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Karpf, A. W. Lasek, T. O. Ririe, A. N. Hanks, D. Grossman, and D. A. Jones Limited Gene Activation in Tumor and Normal Epithelial Cells Treated with the DNA Methyltransferase Inhibitor 5-Aza-2'-deoxycytidine Mol. Pharmacol., January 1, 2004; 65(1): 18 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sato, N. Fukushima, A. Maitra, H. Matsubayashi, C. J. Yeo, J. L. Cameron, R. H. Hruban, and M. Goggins Discovery of Novel Targets for Aberrant Methylation in Pancreatic Carcinoma Using High-Throughput Microarrays Cancer Res., July 1, 2003; 63(13): 3735 - 3742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Shi, S. H. Wei, Y.-W. Leu, F. Rahmatpanah, J. C. Liu, P. S. Yan, K. P. Nephew, and T. H.-M. Huang Triple Analysis of the Cancer Epigenome: An Integrated Microarray System for Assessing Gene Expression, DNA Methylation, and Histone Acetylation Cancer Res., May 1, 2003; 63(9): 2164 - 2171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. DEBINSKI, D. GIBO, and A. MINTZ Epigenetics in High-Grade Astrocytomas: Opportunities for Prevention and Detection of Brain Tumors Ann. N.Y. Acad. Sci., March 1, 2003; 983(1): 232 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. VERMA, B. K. DUNN, S. ROSS, P. JAIN, W. WANG, R. HAYES, and A. UMAR Early Detection and Risk Assessment Proceedings and Recommendations from the Workshop on Epigenetics in Cancer Prevention Ann. N.Y. Acad. Sci., March 1, 2003; 983(1): 298 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sato, N. Maehara, G. H. Su, and M. Goggins Effects of 5-Aza-2'-deoxycytidine on Matrix Metalloproteinase Expression and Pancreatic Cancer Cell Invasiveness J Natl Cancer Inst, February 19, 2003; 95(4): 327 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. El-Osta, M. Lubbert, P. W. Wijermans, T. Licht, and P. A. Jones On the use of DNA methylation inhibitors and the reversal of transcriptional silencing Blood, February 15, 2003; 101(4): 1656 - 1657. [Full Text] [PDF]
|
|
|
|
|
|
F. Sato, D. Shibata, N. Harpaz, Y. Xu, J. Yin, Y. Mori, S. Wang, A. Olaru, E. Deacu, F. M. Selaru, et al. Aberrant Methylation of the HPP1 Gene in Ulcerative Colitis-associated Colorectal Carcinoma Cancer Res., December 1, 2002; 62(23): 6820 - 6822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Harding, K. C. Arden, J. W. Gildea, J. J. Gildea, E. J. Perlman, C. Viars, and D. Theodorescu Functional Genomic Comparison of Lineage-related Human Bladder Cancer Cell Lines with Differing Tumorigenic and Metastatic Potentials by Spectral Karyotyping, Comparative Genomic Hybridization, and a Novel Method of Positional Expression Profiling Cancer Res., December 1, 2002; 62(23): 6981 - 6989. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
